S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:QNRX

Quoin Pharmaceuticals - QNRX Competitors

$4.91
-0.57 (-10.40%)
(As of 08/18/2022 05:45 PM ET)
Add
Compare
Today's Range
$4.71
$5.33
50-Day Range
$3.85
$19.80
52-Week Range
$3.58
$444.00
Volume
2.57 million shs
Average Volume
749,288 shs
Market Capitalization
$3.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00

QNRX vs. RMED, SIGY, NXGL, AVGR, MOTS, DYNT, INVO, STSS, PSTV, and NVIV

Should you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include Ra Medical Systems (RMED), Sigyn Therapeutics (SIGY), NEXGEL (NXGL), Avinger (AVGR), Motus GI (MOTS), Dynatronics (DYNT), INVO Bioscience (INVO), Sharps Technology (STSS), Plus Therapeutics (PSTV), and InVivo Therapeutics (NVIV). These companies are all part of the "surgical & medical instruments" industry.

Quoin Pharmaceuticals vs.

Ra Medical Systems (NYSE:RMED) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Ra Medical Systems has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.

Ra Medical Systems presently has a consensus price target of $12.00, suggesting a potential upside of 7,172.73%. Quoin Pharmaceuticals has a consensus price target of $50.00, suggesting a potential upside of 918.33%. Given Ra Medical Systems' higher possible upside, analysts plainly believe Ra Medical Systems is more favorable than Quoin Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ra Medical Systems
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Quoin Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Ra Medical Systems. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 3 mentions for Ra Medical Systems. Quoin Pharmaceuticals' average media sentiment score of 1.28 beat Ra Medical Systems' score of -1.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ra Medical Systems
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
Quoin Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Quoin Pharmaceuticals has lower revenue, but higher earnings than Ra Medical Systems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ra Medical Systems$20 thousand266.48-$25.07 million-$2.43-0.07
Quoin PharmaceuticalsN/AN/A-$21.46 millionN/AN/A

2.8% of Ra Medical Systems shares are held by institutional investors. Comparatively, 21.7% of Quoin Pharmaceuticals shares are held by institutional investors. 1.0% of Ra Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Quoin Pharmaceuticals has a net margin of 0.00% compared to Ra Medical Systems' net margin of -110,533.34%. Quoin Pharmaceuticals' return on equity of 0.00% beat Ra Medical Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Ra Medical Systems -110,533.34% -146.71% -108.87%
Quoin Pharmaceuticals N/A N/A -355.59%

Ra Medical Systems received 85 more outperform votes than Quoin Pharmaceuticals when rated by MarketBeat users. However, 75.00% of users gave Quoin Pharmaceuticals an outperform vote while only 57.89% of users gave Ra Medical Systems an outperform vote.

CompanyUnderperformOutperform
Ra Medical SystemsOutperform Votes
88
57.89%
Underperform Votes
64
42.11%
Quoin PharmaceuticalsOutperform Votes
3
75.00%
Underperform Votes
1
25.00%

Summary

Quoin Pharmaceuticals beats Ra Medical Systems on 9 of the 14 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QNRX vs. The Competition

MetricQuoin PharmaceuticalsSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$3.94M$3.46B$4.44B$6.29B
Dividend YieldN/A1.58%7.29%3.20%
P/E RatioN/A19.9097.0015.45
Price / SalesN/A66.892,997.57124.91
Price / CashN/A72.8326.2286.60
Price / Book5.015.715.365.97
Net Income-$21.46M$85.56M$167.32M$239.59M
7 Day Performance1.87%-2.86%0.33%0.39%
1 Month Performance-5.35%8.99%8.90%10.43%
1 Year PerformanceN/A-28.31%-28.48%-20.19%

Quoin Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RMED
Ra Medical Systems
1.8334 of 5 stars
$0.17
flat
$12.00
+7,133.3%
-93.3%$5.36M$20,000.00-0.0758Negative News
Gap Up
SIGY
Sigyn Therapeutics
0 of 5 stars
$0.25
flat
$0.93
+273.9%
N/A$9.28MN/A0.005
NXGL
NEXGEL
2.7932 of 5 stars
$1.79
-3.8%
$5.00
+179.3%
N/A$9.97M$1.55M0.0010News Coverage
Gap Up
AVGR
Avinger
1.9736 of 5 stars
$1.76
-0.6%
$24.50
+1,292.0%
-89.7%$10.00M$10.13M-0.3168Earnings Report
Short Interest ↑
Gap Down
MOTS
Motus GI
1.7817 of 5 stars
$3.97
-1.5%
$11.50
+189.7%
-74.0%$10.93M$390,000.00-0.5230Analyst Report
DYNT
Dynatronics
2.3721 of 5 stars
$0.63
flat
$3.50
+458.1%
-45.0%$11.41M$47.80M-62,710.00170Analyst Report
Short Interest ↓
Positive News
Gap Down
INVO
INVO Bioscience
2.0825 of 5 stars
$0.95
-8.7%
$2.50
+163.2%
-76.1%$11.49M$4.16M0.0010Positive News
Gap Down
STSS
Sharps Technology
0 of 5 stars
$1.26
+5.9%
N/AN/A$11.56MN/A0.003Positive News
Gap Up
PSTV
Plus Therapeutics
2.3247 of 5 stars
$0.55
+1.8%
$3.50
+535.2%
-74.3%$12.46M$300,000.00-0.5614Analyst Report
News Coverage
Gap Up
NVIV
InVivo Therapeutics
0 of 5 stars
$9.05
+8.3%
N/A-39.6%$12.59MN/A-1.186Upcoming Earnings
Analyst Report
Positive News
This page (NASDAQ:QNRX) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.